Request a Rep French Fr

Bristol-Myers Squibb
remains committed
to helping you
with your practice

HCP Resources Patient Resources
OPDIVO + YERVOY
Thoracic Dose Card

For patients with previously untreated unresectable malignant pleural mesothelioma/previously untreated NSCLC

DOWNLOAD
OPDIVO GI Dose Card

For patients with HER2 negative advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma (GC/GEJC/EAC), in combination with fluoropyrimidine- and platinum- containing chemotherapy

DOWNLOAD
OPDIVO + YERVOY Safety Profile Leave Behind

For immune-mediated adverse reaction incidences for monotherapy, melanoma, renal cell cancer, non-small-cell lung cancer, and malignant pleural mesothelioma

DOWNLOAD

Please consult the OPDIVO Product Monograph
or click here for important information relating to:

  • The most serious warnings and precautions regarding severe/fatal immune-mediated adverse reactions (imARs), allogeneic hematopoietic stem cell transplantation (HSCT), multiple myeloma and administration under the supervision of physicians experienced in the treatment of cancer.
  • Other relevant warnings and precautions regarding frequency and signs and symptoms of imARs, infusion reaction, patients on controlled sodium diet, haemophagocytic lymphohistiocytosis (HLH), pregnancy, nursing and patients with moderate or severe hepatic or severe renal impairment.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

Please consult the YERVOY Product Monograph
or click here for important information relating to:

  • The most serious warnings and precautions regarding severe/fatal immune-mediated adverse reactions (imARs) and administration under the supervision of physicians experienced in the treatment of cancer.
  • Other relevant warnings and precautions regarding frequency and signs and symptoms of imARs, patients who have had a severe or life-threatening skin adverse reaction on a prior cancer immune stimulatory therapy, haemophagocytic lymphohistiocytosis (HLH), Vogt-Koyanagi-Harada syndrome, serous retinal detachment, Graft-versus-host disease (GVHD), solid organ transplant rejection in the post-market setting, patients on immunosuppressive therapy for life-threatening disease or condition, autoimmune hemolytic anemia, myotoxicity (myositis, myocarditis, and rhabdomyolysis), patients on controlled sodium diet, concurrent administration with vemurafenib, patient counseling information: imARs and fatigue, hepatic impairment, renal impairment, pregnancy, nursing women and required close monitoring.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions